March 31, 2010European Respiratory JournalOpen Access

Asthma and pulmonary arterial hypertension: do they share a key mechanism of pathogenesis?

View Full Paper

Ask AI

Bookmark

Why the study?

Does vasoactive intestinal peptide (VIP) treatment reverse pathological features of asthma and pulmonary arterial hypertension in experimental models?

Population

Experimental models of asthma and pulmonary arterial hypertension, including vasoactive intestinal peptide…

Design

Review

Authors

SSSami I. SaidCambridgeshire and Peterborough NHS Foundation Trust SHSayyed A. HamidiJesse Brown VA Medical Center LBLaura V. González BoscUniversity of New Mexico

Discussion

Member takes

Implication

Does not support VIP therapy in asthma or PAH; leaves open NFAT as shared target in humans.

Structured PICO

Does vasoactive intestinal peptide (VIP) treatment reverse pathological features of asthma and pulmonary arterial hypertension in experimental models?

Population

Experimental models of asthma and pulmonary arterial hypertension, including vasoactive intestinal peptide (VIP) knockout mice

Intervention

Vasoactive intestinal peptide (VIP) treatment

Outcome

Reversibility of airway hyperresponsiveness, airway inflammation, and pulmonary arterial hypertension with vascular remodellingsurrogate

Asthma and pulmonary arterial hypertension may share a common pathogenic mechanism involving NFAT activation, which could be modulated by vasoactive intestinal peptide.

Cite This Study

Said et al. (2010) studied this question.

synapsesocial.com/papers/6a7d675f2935e92dbc7767c1 https://doi.org/10.1183/09031936.00097109

View Full Paper

Ask AI

Bookmark

Asthma and pulmonary arterial hypertension: do they share a key mechanism of pathogenesis?

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Asthma and pulmonary arterial hypertension: do they share a key mechanism of pathogenesis?

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider